What Contrahist Treats: Main Uses and Benefits

Contrahist (Levocetirizine) is a commonly used supportive approach applied across domains where additional symptomatic support is needed. It helps address symptoms related to heightened physiological activity associated with the body’s overreaction to allergens, which may assist with maintaining functional stability during difficult episodes. As a part of symptomatic management, it is commonly used to help with seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria.

Relief from Allergic Manifestations

Contrahist is commonly used across conditions presenting with acute or disruptive episodes. It is applied in addressing symptom clusters that may become intense or disruptive, including runny nose, frequent sneezing, nasal itching, and discomfort such as itchy, watery eyes, contributing to improved day-to-day comfort during symptomatic periods. This medicine is also relevant for easing dermal symptoms.

Management of Persistent Itching and Hives

This medication is considered relevant in clinical settings marked by the heightened distress of chronic idiopathic urticaria (CIU), or long-lasting hives. The medicine is commonly used for managing the uncomplicated skin manifestations of chronic idiopathic urticaria. This may assist with easing the discomfort associated with skin itching (pruritus) and may assist with managing the appearance of wheals (raised welts) that interfere with daily functioning.

---

Quick Fact: Relief for Skin and Nasal Symptoms

Contrahist is relevant for easing itchy eyes and skin pruritus (itching) caused by both seasonal and chronic allergic responses.

Regulatory References

1. NIH DailyMed drug information

Eligibility Map: Who Can and Cannot Use Contrahist (Levocetirizine) — Official Regulatory Information

The eligibility for Contrahist is strictly defined by regulatory authorities based on age, physiological status, and known hypersensitivity.

---

Eligibility Scope

Classification	Population or Condition	Regulatory Status
Allowed Use	Adults and adolescents 12 years and older	Approved for use
Allowed Use	Children 6 months of age and older	Approved for use
Allowed Use	Patients with solely hepatic impairment	No dose adjustment needed
Restricted Use	Adults/adolescents with mild to severe renal impairment	Requires dose adjustment
Restricted Use	Patients with factors predisposing to urinary retention	Use with caution recommended
Conditional Use	Pregnant women	Use only if clearly needed
Not Recommended	Children younger than 6 years (tablet formulation)	Not recommended

---

Absolute Contraindications

Contrahist must not be used by the following groups, as stated in official labeling:

• Patients with a known hypersensitivity to levocetirizine, cetirizine, or any other piperazine derivatives.
• Adults and adolescents with End-Stage Renal Disease (Creatinine Clearance < 10 mL/min) or those undergoing hemodialysis.
• Children 6 months to 11 years of age with any degree of renal impairment.
• Infants younger than 6 months of age.

---

Contrahist’s official interaction profile is defined primarily by two areas: pharmacodynamic reinforcement and alterations to pharmacokinetic clearance. No specific drug-drug or drug-substance combination is formally listed as contraindicated.

---

Interaction Scope

Interaction Domain	Official Regulatory Documentation
Central Nervous System	Co-administration with Alcohol or other CNS depressants (such as sedatives or hypnotics) may cause an additional reduction in alertness and impairment of central nervous system performance.
Exposure Alteration	Studies involving the parent compound (Cetirizine) show that Ritonavir co-use increases drug exposure (AUC) by approximately 40% and decreases apparent total body clearance. Theophylline co-use also resulted in a small decrease in clearance.
Metabolic Potential	Levocetirizine has a low metabolic interaction potential as its metabolism is limited, confirming a negligible risk of clinically significant CYP enzyme-mediated interactions (e.g., inhibition or induction).
Food Effect	Food intake does not alter the total extent of absorption (AUC). However, consumption with food does decrease the rate of absorption, resulting in a lower maximum concentration and a delayed time to reach it.

---

Population-Specific Notes

The regulatory documentation establishes that co-use with substances affecting the Central Nervous System carries a caution for potential additive effects. Since Levocetirizine is substantially excreted by the kidneys, patients with impaired renal function face a greater risk of drug accumulation, which can amplify the severity of any existing interaction. These statements strictly delineate the product's official interaction constraints.

Selective Blockade of the Histamine H1-Receptor

Contrahist's mechanism centers on acting as a high-affinity inverse agonist at the Histamine H1-receptor ( H1R), primarily in peripheral tissues. By stabilizing the inactive conformation of the H1R, the molecule acts to prevent endogenous histamine from triggering cellular signaling cascades, thereby interrupting the signaling cascade initiated by histamine. This action leads directly to the physiological modulation of H1R-driven signaling in vascular and nerve tissues.

---

Modulation of Vascular and Neural Responses

The mechanistic cascade initiated by H1R blockade directly affects two key physiological systems. Preventing histamine from binding to receptors on blood vessels limits the increase in vascular permeability and vasodilation, which in turn restricts the passive leakage of plasma fluid into surrounding tissues. Simultaneously, the drug’s action on peripheral sensory nerves results in the inhibition of sensory nerve depolarization that is typically triggered by histamine.

---

Ancillary Anti-inflammatory Pathway Effects

Beyond the primary H1R mechanism, the drug modulates other components of the inflammatory process. It exerts an effect by inhibiting the migration (chemotaxis) of eosinophils (inflammatory cells) and reducing the release of secondary inflammatory chemicals from mast cells. This ancillary mechanism involves the modulation of cell movement by limiting the accumulation of inflammatory cells at the affected tissue sites.

How to use Contrahist

Contrahist (levocetirizine) is an orally administered medication, available in the form of 5 mg film-coated tablets and an oral solution (2.5 mg per 5 mL). The administration protocol is standardized for once-daily use, with the dose generally taken in the evening. The medicine may be taken without regard to food, meaning it can be consumed either with or without a meal.

Standard and Adjusted Dosing Regimens

The standard regimen for adults and adolescents aged 12 years and older is 5 mg once a day, which is the established maximum daily intake. A lower dose of 2.5 mg once daily may be utilized for some patients, and the 5 mg tablet is scored to facilitate this reduced dosage. For children aged 6 to 11 years, the labeled dose is 2.5 mg once daily, while children 6 months to 5 years are administered 1.25 mg once daily, typically using the oral solution.

Official instructions mandate dose frequency be reduced for individuals with impaired kidney function, with administration potentially occurring once every two or three days, depending on the severity of the impairment. No dose adjustment is required for patients with solely hepatic impairment.

Duration and Missed Doses

Regarding the duration of use, Contrahist may be used intermittently, where administration is stopped upon symptom resolution and restarted upon recurrence. For persistent conditions, continuous therapy may be utilized, with official experience supporting administration for periods up to six months. If a dose is missed, the next dose should be taken at the regularly scheduled time; a double dose must not be taken to compensate.

Contrahist: Recent Clinical Evidence

---

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

The research base for seasonal allergic rhinitis (SAR) relies primarily on short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing participants who received Contrahist to those who received a placebo. Researchers monitored individuals, including Adults and Children as young as 2 years old. Studies monitored outcomes related to physical discomfort by evaluating changes in Total Symptom Scores, which combine measures for the severity of nasal and ocular symptoms, as reported by patients. Regulatory summaries state that certain individual studies reported mixed findings or results that were not consistent with the broader data. Limited information is available for long-term outcomes beyond six months.

---

Evidence for Persistent (Perennial) Allergic Rhinitis

Research on perennial allergic rhinitis (PAR) focuses on conditions characterized by fluctuating manifestations. The evidence includes long-term RCTs where research examined outcomes over several months of daily use, tracking persistent changes in Total Symptom Scores and Health-related Quality of Life (HRQoL). Study populations included Adults, Adolescents, and Pediatric patients starting from 6 months old. Comparative evidence is lacking, as there are few published studies that directly compared Contrahist against other available treatments over these long durations. Data for the very youngest pediatric age groups remain insufficient.

---

Evidence for Chronic Idiopathic Urticaria (CIU)

The evidence for Chronic Idiopathic Urticaria (CIU) includes short-term placebo-controlled RCTs. The research examined conditions associated with acute episodes and monitored Adults, Adolescents, and Children by focusing on Skin Symptom Scores. These scores assessed the severity of pruritus (itching) and the presence of wheals (raised welts). Pharmacological research describes findings related to the measurement of skin changes observed in specific studies. Limited information is available for long-term outcomes, as evidence for sustained management beyond six weeks is scarce.

---

Evidence in Special Populations and Research Gaps

Research has explored the use of Contrahist in various age groups, primarily children and adolescents, with studies designed for different pediatric strata. Evidence also included studies where research examined outcomes for older adults and specific patient groups, such as those with kidney-related conditions. What is still uncertain is the extent of evidence for complex subgroups, such as pregnant populations. Comparative evidence is lacking in many areas; for instance, few direct comparison trials are available against other treatments for the studied conditions. Research exploring the durability of effects after stopping the medication is also limited.

Key Studies & References

1. Levocetirizine Dihydrochloride Tablet - Full Prescribing Information (DailyMed / NIH)

Common questions about Contrahist (FAQ)

Q: What is Contrahist used for?

A: Contrahist is indicated for the temporary relief of symptoms associated with seasonal allergies, such as runny nose, sneezing, itchy eyes, and itching of the nose or throat, according to its approved labeling.

---

Q: Can Contrahist cause drowsiness?

A: The official product information indicates that Contrahist may cause drowsiness in some individuals. It is generally recommended to understand how the medicine affects you before engaging in activities requiring full alertness.

---

Q: When is the best time to take Contrahist?

A: Product labeling does not specify a "best" time for everyone. You should follow the specific instructions provided by your healthcare professional regarding timing, or the directions printed on the package.

---

Q: Is Contrahist safe to take with other medications?

A: Taking Contrahist with other medicines, especially those that also cause sedation or affect the same systems, may increase the risk of side effects. It is important to discuss all current medications and supplements with a healthcare provider or pharmacist before starting Contrahist.

---

Q: How quickly does Contrahist start working?

A: Based on research and product information, the onset of action can vary among individuals. It is typically absorbed and begins to affect symptoms within a timeframe outlined in the clinical data, but individual response may differ.

Contrahist (Levocetirizine) must be stored and handled strictly according to the conditions documented in official regulatory labeling.

Storage Requirements

The medication is required to be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F to 77 F). The product must be kept from freezing and protected from excess heat and moisture.

To preserve stability, the medication must be stored in the container it came in, tightly closed. It must be kept out of the sight and reach of children to satisfy child-safety requirements. Outdated medicine should be properly discarded.

Disposal Instructions

Disposal of any unused or expired Contrahist must be carried out in accordance with local regulatory requirements. Official guidance advises patients to consult a pharmacist regarding proper disposal methods. Specific regulatory documents state that medicines should not be thrown away via wastewater or household waste.